RxDoctor Payments Data

Austin Sue, MD

Hospice and Palliative Medicine · Santa Rosa, CANPI 1487916045

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $113, 2.8 times the $41 reported in 2019.

$398in general payments, 2019–2025

Across 17 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$87
  • Biodelivery Sciences International, Inc.$55
  • Pulmonx Corporation$51
  • Bayer$41
  • Regeneron$38
  • Regeneron Healthcare Solutions, Inc.$36
  • plus $90 from 4 others

What the payments were for

  • Food & beverage$398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$398 in reported general payments places this provider in the 75th percentile of 195 hospice and palliative medicine providers in California.

See all hospice and palliative medicine providers in California

Medicare billing

Part B allowed, 2024
$102,285
Medicare patients
266
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxymorphone Hcl ErOxymorphone Hcl12$22,519
BelbucaBuprenorphine Hcl24$16,811
OxycontinOxycodone Hcl13$10,408
Buprenorphine27$5,199
Oxycodone Hcl143$4,504
Morphine Sulfate ErMorphine Sulfate76$3,357
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$2,871
Methadone Hcl112$1,599
Methenamine Hippurate15$1,543
Hydromorphone Hcl38$1,312
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$1,156
Armodafinil13$860
Morphine Sulfate29$852
Lorazepam71$608
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$87$16,81124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 195 hospice and palliative medicine providers in California.

Other hospice and palliative medicine in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →